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Abstract 
Both adjuvants and focal ablation can alter the local innate immune system and trigger a highly effective systemic 
response. Our goal is to determine the impact of these treatments on directly treated and distant disease and 
the mechanisms for the enhanced response obtained by combinatorial treatments. 
Methods: We combined RNA-sequencing, flow cytometry and TCR-sequencing to dissect the impact of 
immunotherapy and of immunotherapy combined with ablation on local and systemic immune components.  
Results: With administration of a toll-like receptor agonist agonist (CpG) alone or CpG combined with 
same-site ablation, we found dramatic differences between the local and distant tumor environments, where 
the directly treated tumors were skewed to high expression of F4/80, Cd11b and Tnf and the distant tumors to 
enhanced Cd11c, Cd3 and Ifng. When ablation was added to immunotherapy, 100% (n=20/20) of directly 
treated tumors and 90% (n=18/20) of distant tumors were responsive. Comparing the combined 
ablation-immunotherapy treatment to immunotherapy alone, we find three major mechanistic differences. First, 
while ablation alone enhanced intratumoral antigen cross-presentation (up to ~8% of CD45+ cells), systemic 
cross-presentation of tumor antigen remained low. Combining same-site ablation with CpG amplified 
cross-presentation in the draining lymph node (~16% of CD45+ cells) compared to the ablation-only (~0.1% of 
CD45+ cells) and immunotherapy-only cohorts (~10% of CD45+ cells). Macrophages and DCs process and 
present this antigen to CD8+ T-cells, increasing the number of unique T-cell receptor rearrangements in distant 
tumors. Second, type I interferon (IFN) release from tumor cells increased with the ablation-immunotherapy 
treatment as compared with ablation or immunotherapy alone. Type I IFN release is synergistic with toll-like 
receptor activation in enhancing cytokine and chemokine expression. Expression of genes associated with 
T-cell activation and stimulation (Eomes, Prf1 and Icos) was 27, 56 and 89-fold higher with 
ablation-immunotherapy treatment as compared to the no-treatment controls (and 12, 32 and 60-fold higher 
for immunotherapy-only treatment as compared to the no-treatment controls). Third, we found that the 
ablation-immunotherapy treatment polarized macrophages and dendritic cells towards a CD169 subset 
systemically, where CD169+ macrophages are an IFN-enhanced subpopulation associated with dead-cell 
antigen presentation. 
Conclusion: While the local and distant responses are distinct, CpG combined with ablative focal therapy 
drives a highly effective systemic immune response. 
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Introduction 
Checkpoint inhibition strategies result in 
impressive clinical responses in a subset of patients, 
yet patient response remains limited in tumors 
lacking a robust T-cell infiltrate [1]. Response requires 
effective cross-priming of T-cells by the innate 
immune system [2, 3]. Immunotherapy protocols 
incorporate local adjuvants such as CpG (toll-like 
receptor 9 (TLR9) agonist) to enhance the innate 
immune response and cross-priming. Local adjuvants 
can be highly effective [4], particularly when initiated 
while tumors are small [5]. Treatment of larger tumors 
can incorporate surgery or debulking with focal 
therapy. Many clinical cancer treatment protocols 
involve focal ablative therapy (e.g., 47–60% of cancer 
patients receive radiation therapy (RT) over the 
course of their treatment [6]). Therefore, combinations 
of focal therapy and immune adjuvants must be 
optimized, particularly in large lesions. Such focal 
therapies have the potential to offer rapid response by 
inducing immunogenic cell death, releasing 
tumor-associated antigen [7-9] and endogenous 
danger signals [10], increasing tumor infiltrating 
lymphocytes and antigen presenting cells [11, 12], and 
reducing tumor burden and circulating 
immunosuppressive cytokines [13]. We endeavor to 
identify mechanisms by which adjuvant and 
ablation-activated innate immune responses can be 
combined to enhance efficacy.  
Transcriptomic analyses have increasingly been 
adopted to understand immunotherapeutic mecha-
nisms [14-19], and these analyses yield important 
insights into T-cell activity as well as the role of 
specific pathways (e.g., the Wnt pathway) and signals 
(e.g., β-catenin, Wnt7b, Fzd3) in T-cell infiltration. 
Further, they facilitate insight into the relevant 
signaling cascades in the bulk tumor environment. 
For example, recent studies have shown that 
chemotherapy and certain focal ablative therapies 
trigger signaling between the innate and adaptive 
immune systems, in part due to the secretion of type I 
interferons (IFNs) and subsequent expression of 
interferon-stimulated genes (ISGs) [20-22]. More than 
150 ISGs have been reported in this context, many of 
which are traditionally thought to be expressed in 
response to a viral infection, demonstrating the 
unique immune environment created by some 
effective therapies. Type I IFN and TLR9 agonists in 
particular have been shown to alter macrophage 
phenotype in the context of systemic sclerosis [23]; 
yet, less is known about their effects on macrophage 
phenotype in the context of cancer ablative therapies.  
Previously, we demonstrated that ablation 
drastically diminishes viable tumor tissue 24 hours 
after treatment [24]; however, it is still unknown how 
these dead tumor cells within the ablated region are 
processed and presented. Five distinct macrophage 
subpopulations have now been identified: classically- 
activated macrophages (M1), alternatively-activated 
macrophages (M2), tumor-associated macrophages 
(TAM), CD169+ macrophages, and T-cell receptor 
positive (TCR+) macrophages [25]. CD169+ macro-
phages are a class of professional antigen-presenting 
cells (APCs) known to be enhanced by Type I IFN and 
proven to be uniquely capable of cross-priming 
independent of dendritic cells (DCs) [26, 27]. We 
evaluate changes in macrophage and DC number and 
gene expression to determine how such cell types are 
altered by CpG and by ablative therapy. 
High-intensity focused ultrasound and 
high-dose hypofractionated RT are focal ablative 
techniques for the minimally invasive treatment of 
solid tumors. Each stimulates some degree of 
immunization to tumor-associated antigens following 
treatment [28, 29]; but each alone has proven 
insufficient to overcome tumor-mediated immuno-
suppression, thus limiting abscopal effects and the 
ability to treat metastatic disease [30, 31]. Thermal 
treatment with magnetic resonance-guided focused 
ultrasound (MRgFUS) is particularly attractive as 
such treatment is non-invasive and spatially 
delineated, resulting in a precisely controlled 
temperature increase. Under image guidance, a 
fraction of the tumor is ablated and heat-fixed, while 
remaining tumor cells undergo an immunogenic cell 
death over 1-2 days. Moreover, MRgFUS can be 
repeated on a schedule that can be optimized for each 
patient without concern for radiation-mediated 
toxicities, and such treatments have the potential to 
speed cell death as compared with RT. While both 
focal therapies create observable increases in tumor 
infiltration of macrophages and CD8+ and CD4+ 
lymphocytes after treatment, synergistic focal- 
immunotherapy protocols are required to create an 
effective, systemic anti-tumor response [32-34]. 
Although RT is currently the most prevalent clinical 
focal therapy protocol and the most frequently 
explored in combination with immunotherapy [33, 
34], the radiation dose cloud from RT harms 
surrounding normal tissues and may negatively affect 
the immune infiltrate. Recently, the combination of 
MRgFUS ablation and immunomodulatory adjuvants 
has performed well in pre-clinical studies [24]. 
Thermal dosing can be monitored with magnetic 
resonance thermometry to mediate controlled cell 
death to predefined tumor volumes.  
By combining RNA and T-cell receptor 
sequencing (RNA-seq and TCR-seq, respectively) 
with flow cytometry, immunohistochemistry (IHC) 
and quantitative PCR (qPCR), we show for the first 
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time, the distinct effects of adjuvants and ablation on 
the local and distant immune response and their 
impact in driving a T-cell response. We evaluated 
MRgFUS ablation, immunotherapy alone, and 
combined ablative-immunotherapy (AI) in three 
models of multi-focal cancer: the B16-F10/B16-OVA 
model of melanoma, which provides the opportunity 
to assess antigen presentation associated with 
immunogenic cell death [35], the neu exon deletion 
line (NDL), a syngeneic, Erbb2/Her2-driven orthotopic 
model of epithelial, focal, mammary adenocarcinoma 
[36], and the MMTV-PyMT transgenic model of breast 
cancer [37]. In our studies, we created AI protocols by 
combining the checkpoint inhibitor, anti-PD-1, with 
CpG and MRgFUS ablation. Without anti-PD-1, the 
adaptive immune response is muted in either case in 
our models and, therefore, we included anti-PD-1 in 
each local treatment protocol; however, anti-PD-1 is 
delivered systemically and, therefore, does not drive 
the differences between the directly treated and 
distant sites. Through each model, we developed 
mechanistic insights for treatments that bridge a local 
innate immune response and a distant adaptive 
response. 
Results 
We first evaluated the systemic efficacy of 
combining ablation with a potent immunotherapeutic 
regimen and compared the outcome with that 
achieved with immunotherapy alone. Next, we 
determined the impact of ablation and agonists on the 
T-cell population and TCR clones through flow 
cytometry, RNA-seq, and TCR-seq. We then explored 
the mechanisms by which thermal dosing contributes 
to cross-priming and synergizes with a TLR agonist 
including: the dynamics of tumor antigen release and 
subsequent cross-presentation and cross-priming, the 
local release of type I IFNs and expression of ISGs, 
and myeloid cell expansion and phenotypic changes. 
Combining ablation with immunotherapy 
enhances anti-tumor response and generates a 
robust abscopal response  
We first combined MRgFUS ablation and 
immunotherapy to produce a combined ablative- 
immunotherapy (AI) treatment in a murine model of 
primary and distant site mammary adenocarcinoma. 
FVB mice bilaterally transplanted with NDL tumors 
(i.e., HER2+) in the fourth and ninth mammary fat 
pads were administered immunotherapy one week 
prior to the partial ablation of the treated tumor, 
where CpG was intratumorally injected into a single 
tumor and anti-PD-1 was intraperitoneally injected 
(Figure 1A). Treated tumors are denoted as either 
immunotherapy-treated (I-T) or thermal-ablative 
immunotherapy-treated (AI-T), and contralateral 
tumors are denoted as either immunotherapy- 
contralateral (I-C) or thermal-ablative 
immunotherapy-contralateral (AI-C). Across the 
cohort of 118 NDL tumor mice (divided as 45 AI, 35 
immunotherapy-only and 38 no treatment control 
(NTC) mice), tumor volume was similar for the AI 
and immunotherapy-only treated mice at the start of 
treatment.  
The NDL tumor growth reduction resulting from 
the combined AI treatment was greater than that 
achieved with immunotherapy alone at the 38-day 
time point (Figure 1B provides tumor growth data for 
the RNA-seq study, which is representative of the 
entire study). Tumor growth was monitored across 
RNA-seq, TCR-seq and qPCR studies. 100% 
(n=20/20) of AI-T tumors and 90% (n=18/20) of AI-C 
tumors were responsive to AI treatment, where a 
responder was defined as tumor growth at least one 
standard deviation smaller than that of the NTC 
tumors over the course of treatment. The average 
tumor growth during this period (Day 21 to Day 38) 
was -0.013 ± 0.025 cm3 (n=20), 0.07 ± 0.15 cm3 (n=20) 
and 0.33 ± 0.16 cm3 (n=27) for AI-T, AI-C and NTC 
tumors, respectively. The fraction of viable tumor 
cells in AI-T tumors was significantly lower than that 
of the I-T, I-C, or NTC cohorts (Figure 1C). 
Furthermore, viable tumor cells were significantly 
reduced in AI-C, but not I-C, tumors as compared to 
NTC tumors. (Figure 1C).  
In the PyMT model, AI-T tumor growth was also 
suppressed as compared with that of I-T and NTC 
tumors (Figure S1A). We further assessed cell 
viability in AI-T and I-T B16-F10 melanoma tumors at 
day 19 (4 days after ablation). Both treatments 
significantly reduced the number of viable tumor cells 
(Figure S1B), and, on average, AI treatment resulted 
in fewer viable tumor cells as compared with 
immunotherapy alone. Also, in the B16-OVA model, 
at 4 days after ablation, tumor volume was reduced 
by AI treatment in 4 of 5 mice with an average 
reduction of -0.05 cm3 from the start of treatment 
(Figure S1C). At this time point, while tumor growth 
was reduced by immunotherapy alone compared 
with the NTC, only 1 of 5 and 0 of 4 mice regressed in 
the immunotherapy-only and ablation-only cohorts, 
respectively.  
Both directly treated and contralateral tumors 
with associated stroma and immune cells were then 
analyzed using bulk RNA-seq of the tumor tissue. 
Pairwise comparison of treated and NTC tumors 
revealed a maximum differential expression of 10,181 
genes between any two treatment groups (the greatest 
change was between AI-T and NTC). 961 genes were 
differentially expressed between AI-T vs I-T tumors 
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and 451 genes were differentially expressed between 
AI-C vs I-C tumors. We performed a principal 
component analysis (PCA) to elucidate 
transcriptome-wide differences between biological 
groups (Figure 1D). Expression at the directly treated 
and distant tumors clustered into distinct groups, 
suggesting their dramatically different cell 
populations. PCA further revealed that half of the I-C 
tumors cluster with NTC tumors (Figure 1D, black 
circle), demonstrating that immunotherapy alone did 
not notably alter the tumor’s transcriptome in a 
fraction of the distant lesions. The lack of consistent 
response in I-C tumors extends to hierarchical 
clustering of genes corresponding to important cancer 
pathways. For example, the WNT signaling (276 
genes expressed in this model, GO:0060070), MAPK 
cascade (113 genes, GO:0000165), and Cell Cycle (584 
genes, GO:0007049) (Figure S2A-C) ontologies 
indicate that some I-C tumors remained minimally 
affected by treatment. Interestingly, IHC of NDL 
tumors revealed a similar effect, where AI treatment 
dramatically reduced tumor volume in the distant 
lesion by day 38 as compared to the NTC but 
immunotherapy alone did not (Figure 1E). Similarly, 
cancer-related gene expression was reduced following 
AI treatment in genes including Wnt7b, the signaling 
protein essential to canonical Wnt signaling, Erbb2, a 
tumor associated antigen in HER2+ breast cancer, 
Psrc1, the essential regulator of cellular progression 
through mitosis, and S100a14 and Faim2, genes 
associated with inhibition of apoptosis (Figure 
S2D-H). qPCR of Wnt7b on isolated cancer cells 
demonstrates that this pattern largely reflects 
differences in cancer cell number, not changes in 
expression, due to the potency of AI treatment (Figure 
S2I).  
AI treatment enhances the T-cell response in 
distant tumors 
The tumor T-cell infiltrate was investigated with 
flow cytometry and RNA-seq one week after ablation 
(Day 38). Flow cytometry (Figure S3A) demonstrated 
that the frequencies of CD3+, CD4+, and CD8+ T-cells 
were significantly increased in the AI-C tumors as 
compared to all other treatment groups, particularly 
when viewed as a percent of the live cells (Figure 
2A-C). The results were confirmed with IHC of CD8+ 
T-cells at the Day 38 time point in both NDL and 
PyMT tumors (Figure S4). By flow cytometry, the 
frequency of IFN-γ-secreting CD8+ T-cells was 
increased in contralateral tumors treated with both 
immunotherapy protocols (I-C and AI-C) compared 
to the NTC (Figure 2D).  
Expression of Eomes, Prf1 and Icos, genes 
 
 
Figure 1. Thermal ablation with immunotherapy alters the transcriptome and improves the abscopal response in NDL tumor mice. (A) Treatment protocol 
administered to FVB mice orthotopically transplanted with NDL tumors in the fourth and ninth mammary fat pad (n=118). Treatment began on day 21 after implantation and 
assays were conducted on day 31, 34, or 38. Groups included: ablation-immunotherapy (AI) (n=45), immunotherapy-alone (I) (n=35), and no treatment control (NTC, n=38), 
where treated tumors are denoted as either AI-T or I-T, and contralateral tumors are denoted as either AI-C or I-C. (B) Representative volumes of treated and contralateral 
tumors as measured by ultrasound for AI (n=4, 8 tumors), I (n=4, 7 tumors), and NTC (n=5, 10 tumors). (C) Tumor cells were isolated and viability quantified by flow cytometry. 
Groups included: AI (n=8 tumors) or I (n=8 tumors), and NTC (n=6 tumors). *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001 (ANOVA with Fishers LSD test), and †<0.05 
compared to Day 38 NTC (unpaired t-test with Welch’s correction). All data are plotted as mean ± SD. (D) Principal component analysis (PCA) from RNA-seq analysis of 
treated and contralateral tumors as measured by ultrasound for AI-T (n=3, 3 tumors), AI-C (n=3, 3 tumors), I-T (n=3, 3 tumors),  I-C (n=4, 4 tumors) and NTC (n=5, 5 tumors). 
(E) H&E staining in NDL contralateral and NTC tumors at day 38. Scale bars are 2 mm. 
 Theranostics 2018, Vol. 8, Issue 13 
 
 
http://www.thno.org 
3615 
associated with T-cell activation and stimulation, was 
27, 56 and 89-fold higher in the AI-C cohort as 
compared to NTC (compared with 12, 32 and 60-fold 
increases, respectively, for the I-C treatment as 
compared with the NTC). Expression of these genes 
was thus nearly double the level in AI-C as compared 
with the I-C tumors; however, the direct AI-C vs. I-C 
comparison was not significant due to the variability 
in the I-C group (Figure S5A). Genes associated with 
apoptosis (Casp8, Casp9, Faf1) were upregulated in 
AI-C tumors, but not in I-C tumors, as compared to 
the NTC (Figure S5B). Genes associated with 
response to reactive oxygen species (ROS), including 
Txnip and Cat, were also significantly upregulated in 
the AI-C, as compared with the I-C, tumors (Figure 
2E). Chemotaxis annotation (GO:0006935, p<0.03) was 
also significantly upregulated in AI-C, as compared 
with the I-C tumor. Exhaustion markers were 
similarly enhanced with AI treatment or 
immunotherapy alone (Figure S5A). Other cell 
populations (e.g., B- and T-regulatory cells) were low 
in number and not differentially impacted by ablation 
(data not shown).  
To characterize the effects of ablation and 
immunotherapy on T-cell diversity, we sequenced the 
CDR3 region of the TCR beta chain of 
tumor-infiltrating T-cells treated with AI, 
immunotherapy-only, or NTC. Further, we assessed 
systemic T-cells in the blood from a subset of mice 
treated with the AI therapy acquired prior to 
treatment (at day 21, AI-Pre) and at the time of tumor 
harvesting (at day 38, AI-Post). Characterization of 
these CDR3 rearrangements and their frequency 
provide insight into the expansion of specific T-cells 
in response to antigen recognition. 
Pairwise analysis of the proportion of shared 
TCR amino acid sequences (TCR overlap) between all 
samples revealed treatment-specific patterns (Figure 
3A). While TCR overlap between mice is minimal 
before treatment (Figure 3A, black box), 
immunotherapy induces similar CDR3 sequences to 
arise between mice (Figure 3A, green and grey boxes). 
Treatment with immunotherapy increased the TCR 
overlap between tumors of different mice by two-fold 
as compared to the NTC cohort, independent of the 
inclusion of ablation within the protocol. 
Most notably, the addition of ablation to the 
immunotherapy protocol dramatically increased the 
 
Figure 2. AI treatment enhances adaptive immune response in distant tumors. Groups for both flow cytometry and RNA-seq of NDL tumor mice at day 38 as 
treated in Figure 1A included: ablation-immunotherapy (AI), immunotherapy-alone (I), and no treatment control (NTC), where treated tumors are denoted as AI-T or I-T, and 
contralateral tumors are denoted as AI-C or I-C. (A-D) Flow cytometry results for (A) CD3+, (B) CD4+, (C) CD8+ T-cells, and (D) Interferon-gamma secreting CD8+ T-cells. 
AI (n=6 tumors), immunotherapy-alone (n=7 tumors), and NTC (n=4 tumors). * p <0.05, ** p <0.01, *** p <0.001, ****p<0.0001 (ANOVA with Fisher’s LSD test). (E) RNA-seq 
results (samples as in Figure 1D) for genes associated with response to reactive oxygen species (ROS). All data plotted are mean ± SD. For RNA-seq results, bars represent 
significance of at least p < 0.01 as defined by CuffDiff. 
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number of unique CDR3 rearrangements in the 
distant tumor when compared to all other treatment 
groups (Figure 3B). Further, TCR overlap between 
tumors and blood is greater after treatment than 
before treatment in both the directly treated and 
distant tumors with the mean overlap exceeding 0.2 
for blood and distant tumors after treatment (Figure 
3C). Thus, the expansion of TCR-specific clones in 
response to therapy is systemic as both AI-T and AI-C 
have increased TCR overlap in the blood samples 
after treatment (AI-Post). 
In addition, immunotherapy, with or without 
ablation, moved the TCR repertoire of infiltrating 
T-cells to a more monoclonal space (a productive 
clonality closer to 1) when compared to the 
polydisperse (a productive clonality closer to 0) 
repertoire of NTC (Figure 3D). The variability of the 
cumulative frequency of the top 50 clones is smaller 
for the AI treatment than for immunotherapy alone 
(Figure S6A). Similarly, TCR expansion is evident in 
circulating T-cells after, as compared with before, 
treatment (Figure 3E). AI treatment increased the 
cumulative frequency of the top systemic clones by 
1%, a large change when considering the diverse TCR 
repertoire in the blood (Figure S6B). Taken together, 
the results demonstrate that the combination of 
ablation and immunotherapy enhanced the distant 
anti-tumor response, and T-cell expansion and 
activation were factors in the enhanced response.  
Thermal ablation alone mediates tumor 
antigen release and cross-presentation and 
cross-priming; AI treatment greatly enhances 
lymphatic cross-presentation 
We next set out to identify the mechanisms 
responsible for increased T-cell activation and 
expansion after thermal ablation. First, we 
characterized the dynamics of tumor antigen release, 
cross-presentation and cross-priming by the immune 
system after thermal ablation. To do this, we injected 
B16 cells expressing ovalbumin (B16-OVA) at one site 
and a secondary B16 tumor line not expressing the 
cognate antigen (B16-F10) into a distant site in the 
same wildtype immune-competent C57BL/6J mouse. 
A single treatment of either MRgFUS partial ablation 
or hyperthermia was applied to a discrete, central 
region within the B16-OVA tumor 13 days after tumor 
cell transplantation (Figure 4A), and temperature 
profiles of the heated intratumoral volume were 
recorded using MR thermometry. To assess tumor 
antigen uptake and presentation by the immune 
system, we quantified the fraction of antigen 
presenting cells (APCs) displaying the OVA peptide, 
SIINFEKL, bound to the H-2Kb of MHC class I 
molecules in tumors, local and distant inguinal lymph 
nodes, spleen and blood ~2 days after treatment via 
flow cytometry (Figure S7A-B).  
 
 
Figure 3. Thermal ablation increases the number of unique CDR3 rearrangements and TCR overlap between tumor and blood.  Groups for T-cell receptor 
(TCR) sequencing of NDL tumor mice at day 38, as treated in Figure 1A, included: ablation-immunotherapy (AI, n=17 tumors), immunotherapy-alone (I, n=8 tumors), and no 
treatment control (NTC, n=11 tumors), where treated tumors are denoted as AI-T or I-T, and contralateral tumors are denoted as AI-C or I-C. Blood was harvested before 
(AI-Pre, n=5) or after AI treatment (AI-Post, n=5). Data represent two separate experiments and numbers indicate mouse number. (A) Pairwise comparison of the proportion 
of shared TCR clones (TCR overlap) across all samples, including comparisons between AI tumors (green box), NTC tumors (black box), blood before and after AI (pink box), 
and immunotherapy-only tumors (grey box). Pre- and post-blood compared to the AI-T (red box) and AI-C (blue box) tumors are also highlighted. (B) Number of unique TCR 
primary sequences in all tumors. (C) TCR overlap between tumors and blood from the same mouse after treatment. (D) Tumor productive clonality; data are from pooled 
treated and contralateral tumors in each group. Data are mean ± SD. * p <0.05, ** p <0.01 (ANOVA with Fisher’s LSD test). (E) Therapeutic expansion of specific clones in 
blood. All data are mean ± SD. * p <0.05 (unpaired t-test with Welch’s correction). 
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Figure 4. Thermal ablation induces tumor antigen cross-presentation and cross-priming in vivo. (A) B16-F10 and B16-OVA tumors subjected to MRgFUS 
hyperthermia (n=4), MRgFUS ablation (n=5) or no treatment control (NTC, n=15) to assess tumor antigen presentation by antigen-presenting cells (APCs). (B) Flow cytometry 
result obtained ~2 days after ablation or hyperthermia; SIINFEKL bound to H2-Kb of MHC class I molecules on APCs in the tumor was analyzed. * p <0.05, ** p <0.01, *** p 
<0.001, **** p <0.0001, † p<0.01 compared to NTC B16-F10 groups (ANOVA with Fishers LSD test). (C) Representative images of tumor sections from NTC (n=4) and 
ablation-treated (n=2) mice stained for H&E and F4/80 at 48 h. Red arrow indicates hemosiderin laden macrophages within the ablated region. Scale bars are 100 µm. (D-E) Flow 
cytometry result from the B16-OVA unilateral tumor model 7 days after ablation; OVA specific CD8+ T-cells measured via tetramer binding in the (D) tumor and (E) spleen for 
NTC (n=5) and ablation (n=5) cohorts. * p <0.05, and ** p <0.01 (unpaired t-test). (F) Schematic of tumor antigen release, uptake and presentation by APCs after MRgFUS 
ablation. All data are mean ± SD. 
 
Thermal ablation was sufficient to locally 
enhance the tumor fraction of leukocytes, 
macrophages and DCs presenting the OVA SIINFEKL 
peptide (Figure 4B), reaching ~8% of the intratumoral 
CD45+ cells. This effect was temperature dependent, 
as hyperthermia at maximum temperatures of ~50 °C 
did not provide an immunocompetent response. To 
further characterize the SIINFEKL+, CD45+ population 
in tumors directly treated with ablation, we stratified 
these cells into CD11b and CD11c subsets (Figure 
S7C). The greatest fraction of the SIINFEKL+ cells was 
CD11b+CD11c-. SIINFEKL was not enhanced in the 
lymph nodes of ablation-only treated mice at the 48-h 
time point, where the fraction of SIINFEKL+ CD45 
cells was ~0.1% (Figure S7D). SIINFEKL presentation 
by tumor leukocytes was no longer significantly 
enhanced 7 days after ablation (Figure S7E); however, 
the fraction of SIINFEKL+ macrophages in the spleen 
was elevated as a result of ablation 7 days after 
treatment (Figure S7F).  
Tumor IHC at 48 h confirmed that thermal 
ablation increased the numbers of infiltrating 
macrophages (red arrow) within the treated region, 
and the expression of the myeloid cell marker, F4/80, 
in the tumor periphery was dramatically elevated as 
compared to the control (Figure 4C). To verify 
cross-priming after ablation-mediated tumor antigen 
release, we quantified the fraction of CD8+ T-cells 
whose T-cell receptors (TCRs) were specific for the 
MHC-SIINFEKL complex 7 days after treatment via 
flow cytometry using a SIINFEKL-specific MHC-I 
tetramer (Figure S8). We found that thermal ablation 
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significantly increased the fraction of OVA-specific 
CD8+ T-cells in the tumor (Figure 4D) and spleen 
(Figure 4E) of ablation-treated mice. Taken together, 
thermal ablation induces an increase in antigen 
release, cross-presentation, and cross-priming but in 
the absence of immunotherapy is insufficient to 
produce a significant increase in tumor-specific APCs 
in lymph nodes or in the distant tumor (Figure 4F).  
We then studied a unilateral B16-OVA model to 
determine whether immunotherapy priming 
increases the frequency of leukocytes displaying the 
SIINFEKL peptide after ablation (Figure 5A). As in 
other studies, the AI treatment was more effective: the 
fraction of viable tumor cells in AI-T tumors was 
significantly lower than that of both the I-T and NTC 
cohorts (Figure 5B). The frequency of SIINFEKL+ 
leukocytes was increased in the tumor and spleen of 
AI-T and I-T tumors as compared with that of the 
NTC (Figure 5C-D). Further, AI treatment 
significantly elevated the fraction of SIINFEKL+ 
leukocytes in the draining lymph node compared to 
that of the I-T and NTC cohorts (Figure 5E); this is 
greatly enhanced compared to the ablation-only 
results (Figure S7D). Taken together, AI treatment 
amplified cross-presentation in the draining lymph 
node (~16% of CD45+ cells) compared to the ablation 
only (~0.1% of CD45+ cells) and the immunotherapy- 
only cohorts (~10% of CD45+ cells). 
AI treatment induces type I IFN release and 
stimulates ISGs to potentiate inflammatory 
chemokine and cytokine signaling 
Next, we sought to determine the impact of the 
adjuvant CpG and/or ablation on the innate immune 
response. The direct injection of CpG into the directly 
treated tumors resulted in similarly enhanced 
expression of TLR-related signaling components with 
and without ablation (Figure S9A). Despite similarly 
elevated expression of TLR pathway components 
(e.g., Myd88 and Tnf) (Figure S9A), ablation resulted 
in a more robust upregulation of many downstream 
inflammatory and innate immune response ontolo-
gies in AI-T, as compared to I-T tumors (Table S1). 
Gene set enrichment analysis using DAVID 
demonstrated differential upregulation of an 
interferon (IFN) signature in the AI-T, as compared to 
I-T tumors, including the defense response to virus 
ontology (GO:0051607, p<1.50×10-4) [38]. Similarly, 
DAVID identified Herpes simplex infection 
(mmu05168), Measles (mmu05162), Influenza A 
(mmu05164), and Malaria (mmu05144) KEGG 
pathways as upregulated (p<0.05) in AI-T. The 
interferon-stimulated genes (ISGs) (Figure 6A) that 
made up these annotations encode for functions 
including transmembrane receptors associated with 
primary immune response, dsRNA-activated 
enzymes, an RNA-binding protein, the Irf7 
 
 
Figure 5. Quantification of SIINFEKL+ cells in B16-OVA model after AI treatment. (A) B16-OVA tumor cells were injected unilaterally into C57BL/6 mice (day 0). 
Groups included: ablation-immunotherapy (AI, n=5), immunotherapy-alone (I, n=5), and no treatment control (NTC, n=4), where treated tumors and their associated draining 
lymph nodes are denoted as either AI-T or I-T, and contralateral (distant) lymph nodes are denoted as either AI-C or I-C. Tumors, spleen, draining and contralateral (distant) 
lymph nodes were harvested for flow cytometric quantification at ~3 days after ablation. (B) Viable tumor cells quantified by flow cytometry. (C-E) Fraction of SIINFEKL+ 
leukocytes in the (C) tumor, (D) spleen, and (E) lymph nodes. *p<0.05, **p<0.01, *** p <0.001, **** p <0.0001 (ANOVA with Fisher’s LSD test). All data plotted are mean ± SEM. 
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transcription factor and associated regulators, an 
extracellular matrix pattern-recognition molecule for 
microbial pathogens, and an adhesive glycoprotein 
that mediates cell-to-cell and cell-to-matrix 
interactions.  
Based on the increased ISG expression observed 
in the AI-T tumors, we asked whether thermal 
exposure with or without CpG results in the release of 
type I IFN protein from NDL (Figure 6B-C) and 
B16-F10 (Figure 6D-E) tumor cells in vitro. We found a 
significant increase in expression of IFN-α after 
exposure to thermal-ablative temperatures (60 °C) 
combined with CpG, but not by individual treatments 
nor exposure to hyperthermia (42 °C) in NDL cells 
(Figure 6B). In B16-F10 cells, exposure to both 60 °C 
alone and 60 °C+CpG resulted in enhanced release of 
IFN-α (Figure 6D). IFN-β production resulted from 
exposure to the combination of 60 °C and CpG or to 60 
°C alone in both NDL (Figure 6C) and B16-F10 
(Figure 6E) cells. Next, we set out to characterize the 
release of type I IFN from tumors after thermal 
ablation. In bilateral NDL tumor-bearing mice, the 
IFN-α and IFN-β concentrations in blood were 
significantly increased by AI treatment at 6 h after the 
ablation time point (assayed at Day 31) (Figure 6F-G). 
Exposure of cultured NDL cells to IFN-β resulted in 
significantly elevated expression of the ISG Ifi27l2a 
(Figure S9B) as was also observed in Figure 6A. 
Taken together, the results indicate that exposure to 
heat induces type I IFN release, as compared with 
CpG alone across multiple cell types, and further, AI 
treatment enhances the type I IFN protein 
concentration in the blood and local ISGs in vivo. 
Thus, we hypothesize that the ablation-enhanced 
cytokine and chemotactic signaling results from the 
addition of ablation-mediated ISGs to the TLR 
immunotherapy protocol (Figure 6H). 
As a result of the released antigen and ISGs, 
many genes were upregulated in the AI-T, as 
compared with I-T tumors. These differentially 
upregulated signals in the AI-T tumors included 
genes associated with the TNF pathway (KEGG 
mmu04668), including MMPs and cytokines (Figure 
7A, 1st -3rd blocks) and annotations for chemokine 
signaling (mmu04062, p<9.61×10-4) and lymphocyte 
chemotaxis (GO:0048247, p<9.99×10-5) (Figure 7A, 4th 
 
 
Figure 6. Ablative-immunotherapy treatment alters type I interferon gene expression and secretion. In vivo results for gene expression (day 38 in Figure 1A) and 
in vitro and ex vivo results (day 31 in Figure 1A) for IFN production. (A) Groups for RNA-seq of NDL tumor mice as treated in Figure 1A included: ablation-immunotherapy 
(AI), immunotherapy-alone (I), and no treatment control (NTC), where treated tumors are denoted as AI-T or I-T. RNA-seq result for expression of interferon-stimulated genes 
(ISGs) associated with a viral immune response in AI-T (n=3) and I-T (n=3) tumors. (B-E) In-vitro production of IFN-α and IFN-β from (B-C) NDL and (D-E) B16-F10 cells in 
response to heat and CpG. (F-G) In vivo blood plasma concentration of (F) IFN-α (n=12) and (G) IFN-β (n=12) from NDL tumor bearing mice, all assayed by ELISA 6 h after 
ablation. *p<0.05, **p<0.01, ***p<0.001 (ANOVA with Fisher’s LSD test). (H) Schematic of innate immune response due to the combined effects of CpG and thermal ablation. 
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and 5th blocks). Additionally, interleukin 1 receptors, 
Il1r1 and Il1rl1 (Figure 7A, 6th block) and other 
components of pathways associated with leukocyte 
migration during an inflammatory response 
(GO:0003, p<1.75×10-4), positive regulation of 
inflammatory response (GO:0050729, p<1.98×10-7) 
and cytokine-mediated signaling pathway 
(GO:0019221, p<0.002) were upregulated in AI-T, as 
compared with I-T, tumors (Table S1). Expression of 
genes associated with macrophage cytokines (e.g., 
Ccl2, Ccl6, Ccl7, Ccl9, Clc12) and other signals 
associated with monocyte recruitment were 
upregulated in AI-T, as compared with I-T, tumors. 
Ccl2 expression is associated with both the TLR-TNF 
and the ISG-related anti-viral pathways described 
above.  
 
 
 
Figure 7. Ablative-immunotherapy enhances intratumoral macrophages and shifts the macrophage phenotype. Treatment as in Figure 1A for NDL (beginning 
on day 21 after implantation) and PyMT (beginning when tumors reached 0.5 cm in the largest diameter) mice. Groups included: ablation-immunotherapy (AI), 
immunotherapy-alone (I), and no treatment control (NTC), where treated tumors are denoted as AI-T or I-T, and contralateral tumors are denoted as AI-C or I-C. (A) RNA-seq 
results at day 38 (samples as in Figure 1D) for matrix metalloproteinases (block 1), Il6 (block 2), TNF pathway cytokines (block 3), lymphocyte chemotaxis cytokines (4th and 5th 
blocks) and Il1r1 and Il1rl1 (6th block). Heatmaps are normalized by each gene using z-scores of the fragments per kilobase of transcript per million mapped reads (FPKM) values 
across all presented samples. (B) F4/80 IHC in treated and contralateral tumors in the PyMT and NDL models, respectively, as compared to NTC tumors (red arrows indicate 
F4/80 infiltration). Scale bars are 2 mm for whole tumors and 100 µm for 20X images. (C-D) Flow cytometry quantitation of the number of tumor-infiltrating (C) macrophages 
and (D) dendritic cells one week after ablation (day 38): AI (n=10 tumors), immunotherapy-alone (n=10 tumors), and NTC (n=8 tumors). **p<0.01 (ANOVA with Fisher’s LSD 
test). (E) RNA-seq result for expression of the CD169 macrophage markers: Cd169 and Cd206 at day 38. For RNA-seq, bars represent significance of at least p < 0.01 as defined 
by CuffDiff. (F-H) Quantification of macrophages in the (F) spleen, (G) blood and (H) tumors expressing CD169 72 h after ablation (day 34, n=4 animals per group). (I-K) 
Quantification of dendritic cells in the (I) spleen, (J) blood and (K) tumors expressing CD169 72 h after ablation (day 34, n=4 animals per group) *p<0.05, **p<0.01, *** p <0.001, 
**** p <0.0001 (ANOVA with Fisher’s LSD test). All data plotted are mean ± SEM. 
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Both AI treatment and immunotherapy alone 
enhance macrophages in the treated tumors 
and dendritic cells in the distant tumors 
Given the increased expression of chemokines 
and cytokines induced by AI treatment, we 
characterized the myeloid phenotype in the tumor 
immune infiltrate. IHC of NDL and PyMT tumors 
demonstrated the recruitment of infiltrating F4/80+ 
macrophages with both AI and immunotherapy-only 
treatment (Figure 7B). For example, macrophage 
invasion resulting from treatment is evident in the 
AI-T, as compared with I-T tumors in PyMT mice, and 
in AI-C, as compared with the I-C tumors in NDL 
mice. Flow cytometry (Figure S10A) verified the 
increase in the number of tumor-infiltrating 
macrophages in directly treated tumors for I-T and 
AI-T tumors (Figure 7C). Alternatively, the total 
number of intratumoral DCs was not significantly 
elevated compared to the NTC at this time point 
(Figure 7D), suggesting that the F4/80+ expression 
seen in IHC represents a macrophage subset. Genes 
associated with macrophages (Adgre1, Cd68, Cd11b) 
were dramatically enhanced in treated versus distant 
tumors; however, they were not differentially 
enhanced in AI-T as compared with I-T tumors 
(Figure S10B-D).  
Dendritic cell-associated genes (Cd11c, Cd86, 
H2-ab1 and Cd40) were greatly enhanced in the distant 
as compared with the directly treated tumors; 
however, these genes were not differentially 
enhanced in AI as compared with 
immunotherapy-only tumors (Figure S10E). Yet, 
Batf3, required for effective dendritic cross-priming of 
anti-tumor CD8+ T-cells in other focal therapy 
regimes, was significantly enhanced in AI-C but not 
I-C, tumors [39].  
Combining ablation with immunotherapy 
recruits CD169+ macrophages and dendritic 
cells within the tumor 
 Among the markers associated with each of the 
5 sub-classes of macrophages in [25], only gene 
expression associated with the CD169+ macrophage 
(Cd169 and Cd206) was enhanced by AI as compared 
with immunotherapy-only treatment or with the NTC 
tumors (Figure 7E). Alternatively, genes typically 
associated with M2 and tumor-associated 
macrophages (e.g., Cd163) were reduced in the treated 
tumors as compared with the NTC tumor (Figure 
S10F). Cd169 expression is known to be correlated 
with type I IFN levels [40] and mediates sialic 
acid-dependent binding to lymphocytes, facilitating 
direct signaling between tumor-infiltrating 
macrophages and T-cells [27]. To determine whether 
ablation increased the fraction of macrophages 
expressing CD169, we employed flow cytometry 72 h 
after AI and immunotherapy-only treatment (Figure 
S11). CD169 was elevated in macrophages (F4/80+, 
CD11b+, CD45+ cells) in the spleen and blood for both 
AI and immunotherapy-only treatment (Figure 7F-G). 
This CD169+ macrophage population was also 
significantly increased in AI-T tumors compared to 
I-T and I-C tumors (Figure 7H), suggesting that, while 
CpG enhanced the circulating population, ablation 
increased the tumoral recruitment of CD169+ 
macrophages.  
We next investigated the impact of thermal 
ablation on DCs in the context of CD169 expression. 
While DCs (MHCII+, CD11c+, CD45+ cells) expressing 
CD169 were not significantly altered in the spleen or 
blood compared to the NTC (Figure 7I-J), the fraction 
of CD169+ DCs in AI-T tumors was elevated 
compared to that of NTC tumors (Figure 7K). The 
fraction of DCs displaying CD169 (~9%) was smaller 
than the CD169+ macrophage fraction (~28%).  
Lastly, we set out to elucidate the co-expression 
of CD169 and tumor antigen on APCs using a 
unilateral B16-OVA model using the protocol in 
Figure 5A. Direct treatment of a single B16-OVA 
tumor with immunotherapy was sufficient to increase 
the total fraction of CD169+ cells to ~9% of leukocytes 
in distant lymph nodes 72 h after treatment (Figure 
S12A). Interestingly, AI treatment significantly 
increased the fraction of nodal cells displaying both 
SIINFEKL and CD169 (Figure S12B). Of those 
double-positive cells, AI treatment significantly 
increased both SIINFEKL+, CD169+ DCs (Figure 
S12C) and SIINFEKL+, CD169+ macrophages (Figure 
S12D) compared to immunotherapy alone and NTC.  
Discussion 
The treatment of solid tumors, especially those 
that are non-T-cell inflamed, is challenging as it can be 
difficult to overcome immunosuppression dictated by 
the local tumor microenvironment and cytokine 
milieu. In the mouse models we have studied, we 
have previously demonstrated that the effect of 
ablation alone on distant immune populations and 
distant tumor growth and survival is not significant 
[24]. Yet, therapeutic efficacy is enhanced by a 
well-designed protocol combining ablation with 
immunotherapy as compared with immunotherapy 
alone [24]. We have therefore focused on this direct 
comparison between ablation-immunotherapy and 
immunotherapy-only protocols, and specifically 
characterized the mechanistic differences.  
The AI treatment protocol applied here begins 
by priming the immune system with CpG and 
anti-PD-1, and this combination expands macrophage 
and T-cell populations and TCR clones (Figure 8, step 
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1). MRgFUS is then applied to raise the temperature 
within a focal region of the tumor to ~60 °C, creating a 
small heat-fixed lesion surrounded by a hyperthermic 
tumor rim in which heat-mediated death occurs and 
type I IFN and antigen are released over a period of 
hours (Figure 8, step 2). The CD169+ myeloid 
population (macrophages and DCs) is enhanced 
within the tumor following ablation (Figure 8, step 3). 
We then observe clonal expansion and an increase in 
antigen-specific CD8+ T-cells with AI treatment 
(Figure 8, step 4).  
Mechanistic differences for the enhanced 
response from AI treatment in the directly 
treated tumor 
We found three major mechanistic differences 
when ablation was added to immunotherapy. First, 
thermal dosing mediated the release of tumor antigen; 
macrophages and DCs processed and presented this 
antigen to CD8+ T-cells, which generated specific TCR 
clones. Our data demonstrate that partial tumor 
ablation with MRgFUS (without immunotherapy) 
promoted recruitment and infiltration of myeloid cells 
to the tumor nest and locally released tumor antigen 
in an immunocompetent manner. These professional 
cells provided cross-priming to MHC-I restricted 
cytotoxic lymphocytes (CTLs) one week after ablation. 
Further, the addition of CpG to same-site ablation 
significantly enhanced cross-presentation of tumor 
antigen in the draining lymph nodes compared to 
ablation-only and immunotherapy-only cohorts.  
 Second, when ablation was combined with CpG, 
type I IFN release from tumor cells was greater as 
compared with immunotherapy or heat treatment 
alone. This is the first such report demonstrating the 
release of type I IFN from tumor cells due to thermal 
ablation. We find that this type I IFN production by 
tumor cells varies between tumor lines and should be 
further investigated to determine whether this is a 
major source of the differences in abscopal response 
between patients. The IFN release induced a viral-like 
immune response in the AI-T tumors, including the 
elevation of ISGs involved in polynucleotide sensing 
and the binding of non-self RNA. The combination of 
type I IFN resulting from ablation and introduction of 
a TLR9 agonist can be synergistic and induce further 
type I IFN production through Irf7 signaling (Figure 
6A). With our AI treatment protocols, the Irf7 
transcription factor was significantly enhanced in 
AI-T, as compared with I-T, tumors. The enhanced 
 
Figure 8. Schematic of the AI-induced immune effects. Illustration depicting the immune effects through the multi-stage therapeutic protocol of AI treatment. First, 
immunotherapy bolsters the number of tumor-infiltrating CD8+ T-cells and macrophages, enhances TLR expression and increases the systemic CD169+ subpopulation (Step 1). 
Second, MRgFUS ablation releases tumor antigen, inflammatory chemokines and cytokines, enhances interferon stimulating genes (ISGs) and alters local macrophage phenotype 
(Step 2). Cross-presentation and cross-priming, mediated by macrophages and DCs, occurs to drive the clonal expansion of tumor-specific CD8+ T-cells (Step 3) and results in 
an effective abscopal response (Step 4). 
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TLR-TNF and IFN-related signaling were expected to 
upregulate MMPs, cytokines and chemokines 
associated with lymphocyte recruitment and indeed, 
these changes were observed with RNA-seq. By IHC 
and flow cytometry, we observed that inflammatory 
myeloid cells invaded the AI-T and AI-C tumors. 
Further, downstream genes for lymphocyte 
chemotaxis were elevated in AI-T tumors only, 
demonstrating the potential of MRgFUS ablation to 
convert the local innate immune response into an 
adaptive immune response. 
Third, we found that the TLR9 agonist polarizes 
macrophages and DCs towards a CD169 subset 
systemically. Of the 5 macrophage phenotypes 
described in [25], only systemic CD169+ macrophages, 
a class of APCs known to be enhanced by type I IFN 
and proven to be capable of cross-priming, were 
expanded [26, 27]. Genes associated with M2 
macrophage markers were reduced. CD169+ cells 
were elevated in the spleen and blood of treated mice, 
and the fraction of macrophages was 3 to 5-fold 
greater than DCs. After ablation, the fraction of 
CD169+ DCs and macrophages was elevated at the 
site of the local injury, with a greater fraction of 
macrophages observed in this subset. One previous 
report has indicated that type I IFN and TLR9 agonists 
in particular enhance the expression of CD169 in the 
context of systemic sclerosis [23]. Given the recent 
reports of successful immunotherapy protocols 
incorporating CpG as a TLR9 agonist, recognition of 
the potential role of CD169+ myeloid cells in 
cross-priming is important [4]. Our results 
demonstrate that AI treatment increases the fraction 
of tumor antigen-presenting CD169+ DCs and 
macrophages in distant lymph nodes 3 days after 
ablation. These data suggest that macrophages and 
DCs expressing CD169+ are regulators of systemic 
T-cell activation after thermal ablation, which may be 
an important contributor for bolstering the abscopal 
effect of TLR agonists. This is the first such report 
describing the role of CD169+ myeloid cells after 
thermal ablation and the differential role of 
macrophages and DCs, including the Batf3 subtype, 
will be the focus of future work.  
AI treatment enhances T-cell number, TCR 
diversity and T-cell-mediated distant response 
As a result of the enhanced priming at the 
directly treated site, the systemic T-cell populations 
were altered. We explored TCR expression through 
TCR-seq. T-cell antigen specificity is conferred 
through the TCR, a membrane-bound protein found 
on the surface of T lymphocytes. We found that the 
unique rearrangements in the tumor were increased 
by AI treatment. Comparing the TCR of circulating 
T-cells in the blood before and after treatment also 
demonstrated differences in expression with greater 
similarity between tumor and blood observed after 
treatment. This result is encouraging for sampling 
treatment response in blood after therapy.  
The enhanced T-cell response is also supported 
by greatly enhanced T-cell numbers and by enhanced 
genes associated with T-cell activation and 
stimulation. Eomes, Prf1 and Icos expression was up to 
89-fold higher in the AI-C cohort as compared to the 
NTC and nearly double the level in AI-C as compared 
with the I-C tumors. While we observed significantly 
enhanced expression of Fas, Tnf, Casp8, and Casp9 in 
all directly treated tumors, in the distant tumors, only 
AI treatment differentially enhanced Faf1, Casp8 and 
Casp9. Casp8 activation is reported to have the greatest 
impact on IFN-induced apoptosis; the increase in 
caspase expression observed here has the potential to 
sensitize cells to apoptosis [41].  
Bulk RNAseq analysis was validated by flow 
cytometry and qPCR 
We chose to combine a bulk RNA-seq analysis 
with selected qPCR of sorted cells. This provided the 
opportunity to compare gene expression over 
multiple treatment groups and to assess both the 
relative frequency of cellular phenotypes and specific 
aspects of individual tumor, immune and stromal 
cells. Our results, with the cancer cell, macrophage 
and T-cell population differences across treatment 
groups validated by flow cytometry, demonstrate the 
power of such analysis in differentiating the impact of 
therapeutic components. Treatment-related changes 
in cancer cell, T-cell and macrophage markers were 
evident in the unsorted RNA-seq and flow cytometry 
datasets. The principal component, functional 
annotation, and hierarchical clustering analyses 
clearly demonstrated that the directly treated and 
distant tumors had distinct gene expression patterns 
across many cellular functions. Further, a fraction of 
the immunotherapy-treated animals did not 
significantly respond to treatment and, therefore, 
clustered with the NTC. While the analyses detected 
the expected effects of the TLR agonist, CpG, and 
checkpoint inhibitor, anti-PD-1, shared in all treated 
mice, important mechanistic differences between the 
AI and immunotherapy-only treatments were also 
detected by RNA-seq.  
With administration of a TLR agonist (CpG) 
alone or CpG combined with same-site ablation, we 
found dramatic differences between the local and 
distant tumor environments. With both ablation- 
immunotherapy and immunotherapy alone, directly 
treated tumors were skewed to high expression of 
F4/80, Cd11b and Tnf, and the distant tumors to 
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enhanced Cd11c, Cd3 and Ifng. These extensive 
differences were evident through the RNA-seq 
analysis. 
Thermal ablation can enhance the speed and 
spatial precision of treatment as compared 
with RT 
Thermal ablation mediates rapid, immunogenic 
cell death (1-2 days) that is capable of driving a 
tumor-specific immune response. Thermal dosing 
with MRgFUS can be tightly controlled in a 
spatiotemporal manner and repeated within the same 
treatment volume. Protocols combining immunother-
apy with RT are now widespread [30, 33]; however, 
mitotic catastrophe and subsequent cell death in 
irradiated cells can require up to one week to develop. 
Further, radiation is known to induce “bystander 
effects”, or chromosomal damage consistent with 
ionizing radiation in non-irradiated (non-targeted), 
neighboring cells, as previously demonstrated in 
lymphocytes, fibroblasts, keratinocytes and 
endothelial cells [42]. Approximately 10% of the RT 
dose is expected to impact tissue 10 cm away from the 
target site [43]. Deciphering radiation-induced 
bystander effects in real-time is challenging, as the 
local microenvironment of the irradiated site 
undergoes a complex wound healing process. Thus, to 
ensure tumor control and patient safety, the number 
of radiation treatments at a single location is 
restricted. MRgFUS provides greater flexibility in 
structuring such treatment protocols. 
In summary, dramatic differences between local 
and systemic tumor immune infiltrates result from 
adjuvants applied with or without ablation. A 
multi-step protocol in which immunotherapy 
expands T-cells and macrophages, followed by partial 
ablation, enhances antigen presentation and type I 
IFN release, alters the myeloid phenotype to enhance 
cross-priming, and results in a robust adaptive 
immune response. 
Methods 
Study design 
The research objective of these studies was to 
evaluate the immunological and transcriptome 
alterations created by combining MRgFUS ablation 
with immunotherapy. We hypothesized that tumor 
debulking with thermal ablation would induce a 
potent, local innate immune response to potentiate an 
abscopal immune response. A combination of 
RNA-seq, TCR-seq, flow cytometry, ELISA 
(enzyme-linked immunosorbent assay), qPCR and 
IHC were performed to investigate the immune 
phenotype at different points throughout the 
treatment protocol. All animals and cells used in these 
studies were randomized to biological groups, and 
were performed with the appropriate controls, which 
are reported in the figure legends. Tumors were 
continuously measured with ultrasound, and therapy 
was started once tumors reached 5 mm in the largest 
diameter. All data in the figures are presented as 
means ± SD.  
Cell lines 
B16-F10 cells were purchased from American 
Type Culture Collection (ATCC, #CRL-6475), and 
B16-OVA cells, genetically modified to express 
chicken ovalbumin (OVA), were a generous gift from 
the William Murphy Laboratory (UC Davis, Davis, 
CA). Cells were cultured in high-glucose DMEM 
(Gibco, #11995) containing 10% FBS and 1% 
penicillin-streptomycin in a 37 °C humidified 
chamber containing 5% CO2. B16-F10 and B16-OVA 
cells were passaged at a density of 1-3×106 into 175 
cm2 tissue culture flasks (VWR, Radnor PA). Once 
cells reached 85-90% confluency, approximately 4 
days after plating, they were collected and 
resuspended in 1:1 Matrigel (Corning, #356234): PBS 
without calcium and magnesium (PBS-/-) for 
injection into mice.  
Study approval 
All animal experiments were conducted with 
approval from the University of California, Davis, 
(Davis, California) Institutional Animal Care and Use 
Committee (IACUC).  
Animal models  
A total of 193 mice were studied (118 bilateral 
NDL, 24 B16-F10/B16-OVA, 23 unilateral B16-OVA, 4 
CAG OVA, 10 B16-F10 bilateral and 14 PyMT 
tumor-bearing mice) with the study breakdown in 
Table S2. For all relevant groups, anti-PD-1 was 
injected intraperitoneally (i.p.) at a dose of 200 µg, as 
in [44] and CpG was injected intratumorally (i.t.) into 
a single tumor at a dose of 100 µg, as in [45]. All same 
day treatments with ablation and immunotherapy 
involved injections administered immediately 
following MRgFUS ablation.  
Therapeutic and sequencing protocols in the 
NDL or PyMT model 
The neu exon deletion line (NDL), a syngeneic 
model of mammary adenocarcinoma, was obtained 
from the Alexander Borowsky Laboratory (UC Davis, 
Davis, CA). Four- to five-week-old FVB/n female 
mice purchased from Charles River (Wilmington, 
MA) were bilaterally transplanted with NDL tumor 
biopsies (~1 mm3) into the fourth and ninth inguinal 
mammary fat pads. Approximately 21 days later, 
mice were randomized into treatment groups with 
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average tumor sizes ranging between 4-6 mm in the 
longest dimension as measured by ultrasound 
(Sequoia, Siemens Preclinical Solutions).  
NDL mice treated with immunotherapy received 
injections of CpG into a single tumor on days 21, 24, 
28, and 31 after tumor transplantation; anti-PD-1 was 
injected on days 21, 28 and 35 after tumor 
transplantation (see Figure 1A). In the NDL protocols, 
MRgFUS ablation was performed in a single tumor on 
day 31 after a course of immunotherapy as in [24]. The 
IFN level was assayed in blood on day 31 (6 h after 
ablation) by ELISA. NDL mice treated with 
immunotherapy with and without ablation were 
euthanized on day 34 or 38; the tumors were 
harvested and processed for RNA-seq, TCR-seq, flow 
cytometry, qPCR or IHC. Additionally, blood was 
harvested and processed on day 31, 34 or 38, and 
spleens were harvested and processed on day 34 for 
flow cytometry quantification.  
FVB/N-Tg(MMTV-PyVT)634Mul/J transgene 
female mice (5 weeks old) were purchased from The 
Jackson Laboratory. Once tumors reached approxi-
mately 5 mm in the largest dimension, they were 
randomized into treatment groups (~10 weeks old). 
With the exception of the starting time point, the 
treatment protocol administered was the same as that 
in NDL mice in Figure 1A. Timing corresponds to 
days after the start of the treatment. CpG was 
administered into a single tumor on days 0, 3, 7, and 
10; anti-PD-1 was injected on days 0, 3 and 14; and 
thermal ablation was administered on day 10.  
In vivo tumor antigen release studies in 
B16-F10 and B16-OVA models 
C57BL/6J female mice (7 weeks old, 15–25 g) 
were purchased from The Jackson Laboratory (Bar 
Harbor, ME).  
Ablation or hyperthermia alone and controls 
(Figure 4A): A B16-F10/B16-OVA dual tumor model 
and appropriate controls were studied. Mice were 
subcutaneously (s.c.) injected with B16-F10 (3×105 
B16-F10 cells per 50 μL Matrigel:PBS-/-) and 
B16-OVA cells (6×105 B16-OVA cells per 50 μL 
Matrigel:PBS-/-) in the left and right flank, 
respectively. Negative control mice bearing bilateral 
B16-F10 control tumors were injected s.c. with 
B16-F10 cells (2.5×105 cells per 50 μL Matrigel:PBS-/-) 
into the left and right flanks. C57BL/6- 
Tg(CAG-OVA)916Jen/J (CAG-OVA) mice (6 weeks 
old, 15–25 g) were purchased from The Jackson 
Laboratory and studied as positive controls.  
For the ablation- and hyperthermia-only groups, 
MRgFUS was directed to the B16-OVA tumor on day 
13 after tumor cell injection (approximately 5 mm in 
the largest diameter). The mice were euthanized 
either on day 15 or 20 post tumor cell implant (2 or 7 
days after treatment). Tumors and their respective 
draining inguinal lymph nodes, as well as the spleen 
and blood were dissected and harvested for flow 
cytometry or IHC.  
Ablation with immunotherapy (Figure 5A): For 
B16 studies incorporating immunotherapy, a 
unilateral B16-OVA tumor model was studied, where 
mice received s.c. injections (4-6×105 cells per 50 μL 
Matrigel:PBS-/-) into the left flank only. 
Immunotherapy was administered before and with 
thermal ablation (CpG, days 7, 8, 9, and 11 post tumor 
cell implantation; anti-PD-1, days 7 and 9 post tumor 
cell implant). For the AI cohort, ablation was 
administered on day 11. Tumors, both inguinal lymph 
nodes (right and left side), spleen and blood were 
harvested on day 14 after tumor cell implant for flow 
cytometry. In this study, the draining lymph node is 
defined as the inguinal node adjacent to the treated 
B16-OVA tumor (AI-T or I-T) and the distant lymph 
node is the inguinal lymph node on the contralateral 
side with no tumor (AI-C or I-C).  
MRgFUS ablation protocol 
MRgFUS ablation and hyperthermia were 
performed with a MR-guided pre-clinical HIFU 
system (Image Guided Therapy) using a 16-element 
annular array transducer at 3 MHz (Imasonic SAS), on 
a Bruker BioSpec 7 T small animal MR system (Bruker 
Biospin), as previously described [46]. The thermal 
ablation treatment plan was designed to heat a 
discrete region (2-3 mm) within a tumor volume to 
temperatures above 60 °C, where a thermal dose in 
cumulative equivalent minutes at 43 °C (CEM43) of 
more than 5,000 was achieved. 
Reagents  
TLR9 agonist, CpG 1826 (class B), was purchased 
from InvivoGen (San Diego, CA). Anti-PD-1 (CD279) 
mAb (rat IgG2a, clone RMP1-14), was purchased from 
Bio X Cell (West Lebanon, NH). iTAG MHC murine 
tetramer H-2 kb OVA conjugated to phycoerythrin 
(PE) was purchased from MBL International 
(#T03000, Woburn, MA).  
High-throughput TCR-β sequencing  
TCR-β CDR3 regions were amplified and 
sequenced on the ImmunoSEQ platform (Adaptive 
Biotechnologies, Seattle, WA, USA). Data from the 
productive reads were uploaded to the 
ImmuneACCESS provided by Adaptive Biotech. 
Diversity metrics, sample overlaps, and frequency 
tables were downloaded from the ImmunoSeq 
Analyzer tool and processed in MATLAB and in 
VDJTools [47].  
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In vitro and in vivo IFN-α and IFN-β ELISA 
studies 
NDL or B16-F10 tumor cells were plated in 
12-well tissue-culture treated plates at a concentration 
of 3.5×105 or 3×105 cells/well, respectively. Cells were 
cultured overnight in 1 mL high-glucose DMEM 
(Gibco, #11995) containing 10% FBS and 1% 
penicillin-streptomycin in a 37 °C humidified 
chamber containing 5% CO2. The next day, the cell 
media was removed and replaced with 500 μL of 
pre-warmed media. The biological groups were the 
following: 37 °C (n=6), 37 °C+CpG (n=3), 42 °C (n=3), 
60 °C (n=6), or 60 °C+CpG (n=6). These samples were 
then placed in the respective water bath (37 °C, 42 °C, 
or 60 °C) for 1 min, removed, and allowed to cool to 
room temperature for 5 min, followed by addition of 
CpG (5 μg/ 500 μL) to the appropriate dishes. Cells 
were then incubated continuously for 24 h in a 37 °C 
humidified chamber containing 5% CO2. After 24 h, 
the cell culture medium was collected, centrifuged 
(300 ×g, 10 min, 4 °C), and the supernatant was 
collected for IFN-α and IFN-β ELISA quantification 
(#42115 and 42410, respectively, PBL Assay Science, 
Piscataway, NJ). IFN-α and IFN-β supernatant 
concentrations were normalized to total cell number 
for each sample.  
For the type-1 IFN in vivo study, blood was 
harvested via retro-orbital collection from bilateral 
NDL mice treated as in Figure 1A, 6 h after ablation 
on Day 31 post tumor implant. Blood was processed 
to plasma by centrifugation at 1000 ×g for 10 min at 4 
ºC and frozen at -80 ºC until IFN-α and IFN-β protein 
measurement via ELISA as above.  
Statistical analysis 
Statistical analyses were performed using Prism 
7 software (GraphPad Software Inc.). Results are 
presented as mean ± SD, unless otherwise indicated. 
For analysis of three or more groups, a one-way 
ANOVA test was performed followed by a Fisher’s 
LSD test without multiple comparisons correction in 
GraphPad Prism. Analysis of differences between two 
normally distributed test groups was performed 
using an unpaired t-test assuming unequal variance. 
P values less than 0.05 were considered significant. 
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